

The Importance of Strategy in the Early Stages of Drug Development

Ronan Bouër (Executive Director, Syneos Health)
2024. 10. 16, PM. 04:30-07:00
KPBMA Building K room

[참가신청서링크 +](#)

Introduction

Korea Innovative Medicines Consortium

Dr. Bouër's presentation will focus on early preclinical-stage drugs designed to create new therapeutic solutions for patients. He will discuss the critical elements that should typically be considered when developing an initial project strategy from scratch—comprehensively, ambitiously, yet pragmatically. This approach is aimed at helping to engage early with key stakeholders, including potential funding partners. Among the topics, he will highlight the importance of crafting a tailored early clinical strategy aligned with the indication, usually informed by scientific assessment, mechanism of action, or prior experience with similar assets. Additionally, Dr. Bouër will explore key factors relevant to selecting the indication for clinical proof of value, including examples from Syneos Health's Virtual Incubator Pilot Case Studies.

About the Speaker

Korea Innovative Medicines Consortium



Ronan Bouër, PharmD, Ph.D, MBA

Executive Director, Scientific & Business Advisor
for Translational Sciences & Virtual Incubator,
Syneos Health

Dr. Ronan Bouër brings over 25 years of experience in the pharmaceutical and biotech industries, along with 6 years in hospital and university settings. He has held key roles in toxicology, pharmacokinetics, and bioanalytics, including leadership positions at Abbott/Fournier and Galderma R&D. For the past 5 years, he has been with Syneos Health as the Executive Director for Early Phase and Virtual Incubator, where he focuses on optimizing development processes and transitioning projects to early clinical stages. Dr. Bouër is deeply involved in portfolio management, due diligence, and supporting early-stage biotechs in building strong projects and securing funding.

Syneos Health: Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.

Virtual Incubator: With a global presence and a proven track record in supporting over 90% of products granted marketing authorization by the FDA and EMA in the past five years, Syneos Health is at the forefront of accelerating drug development and commercialization. Our specialized Virtual Accelerator model offers a strategic vision for early-stage assets, helping biotech companies fast-track their projects to market readiness.